European guidelines on managing adverse effects of medication for ADHD

J. Graham (1) , T. Banaschewski (2, 3) , J. Buitelaar (4) , D. Coghill (5) , M. Danckaerts (6) , R. W. Dittmann (7) , M. Döpfner (8) , R. Hamilton (9) , C. Hollis (10) , M. Holtmann (2) , M. Hulpke-Wette (11) , M. Lecendreux (12) , E. Rosenthal (13) , A. Rothenberger (3) , P. Santosh (14) , J. Sergeant (15) , E. Simonoff (16) , E. Sonuga-Barke (17, 18) , I. C. K. Wong (19) , A. Zuddas (20) , H.-C. Steinhausen (21) , E. Taylor (22)

1 Child and Adolescent Psychiatry
2 Department of Child and Adolescent Psychiatry and Psychotherapy
3 Department of Child and Adolescent Psychiatry
4 Karakter Child and Adolescent Psychiatry University Centre [Nijmegen]
5 Centre for Neuroscience
6 Department Child and Adolescent Psychiatry
7 Psychosomatic Department, Children's Hospital
8 Psychiatry and Psychotherapy of Childhood and Adolescence
9 SickKids - The Hospital for sick children [Toronto]
10 Section of Developmental Psychiatry, Division of Psychiatry
11 Pediatric Cardiology
12 Child and Adolescent Psychopathology Unit, Robert Debre Hospital
13 Evelina London Children's Hospital
14 Department of Psychological Medicine
15 Department of Clinical Neuropsychology, Faculty of Psychology and Education
16 Social, Developmental and Psychiatry Research Centre
17 School of Psychology
18 Department of Experimental Clinical and Health Psychology
19 University of London and Institute of Child Health
20 Child Neuropsychiatry, Department of Neuroscience
21 Department of Child and Adolescent Psychiatry
22 MRC Social Genetic Developmental and Psychiatry Centre

The safety of ADHD medications is not fully known. Concerns have arisen about both a lack of contemporary-standard information about medications first licensed several decades ago, and signals of possible harm arising from more recently developed medications. These relate to both relatively minor adverse effects and extremely serious issues such as sudden cardiac death and suicidality. A guidelines group of the European Network for Hyperkinetic Disorders (EUNETHYDIS) has therefore reviewed the literature, recruited renowned clinical subspecialists and consulted as a group to examine these concerns. Some of the effects examined appeared to be minimal in impact or difficult to distinguish from risk to untreated populations. However, several areas require further study to allow a more precise understanding of these risks.

Mots clés: ADHD; HKS; Medication; Adverse; Guidelines; European; Children

J. Graham, T. Banaschewski, J. Buitelaar, D. Coghill, M. Danckaerts, et al.. European guidelines on managing adverse effects of medication for ADHD. European Child and Adolescent Psychiatry, 2010, 20 (1), pp.17-37. ⟨10.1007/s00787-010-0140-6⟩. ⟨hal-00637792⟩